Last reviewed · How we verify

Iqirvo — Competitive Intelligence Brief

Iqirvo (ELAFIBRANOR) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Peroxisome Proliferator-activated Receptor Agonist [EPC]. Area: Metabolic.

marketed Peroxisome Proliferator-activated Receptor Agonist [EPC] Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Iqirvo (ELAFIBRANOR) — Ipsen. Iqirvo works by activating peroxisome proliferator-activated receptors to improve liver function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Iqirvo TARGET ELAFIBRANOR Ipsen marketed Peroxisome Proliferator-activated Receptor Agonist [EPC] 2024-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Peroxisome Proliferator-activated Receptor Agonist [EPC] class)

  1. Ipsen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Iqirvo — Competitive Intelligence Brief. https://druglandscape.com/ci/elafibranor. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: